Stryker (SYK) · Medical Devices
Stryker Q2 2026 earnings: summary, key numbers & outlook
Results filed 30 Jul 2026 · Quarter ended 30 Jun 2026
Press release ↗Investor relations ↗
Summaries and transcripts are machine-generated and can contain errors.
In brief
Stryker is recovering from a cyber incident that disrupted supply and left backorders, while Mako installations hit a record Q2 and Triathlon Gold moves toward full commercial launch.
Stryker's quarter was shaped by its recovery from the cybersecurity incident first reported on March 11, 2026. Production ramped back up, but the supply disruption left a meaningful backorder situation and lost sales. Even so, sales grew on higher unit volume across MedSurg and Neurotechnology and Orthopaedics, and Stryker delivered its best ever Q2 for Mako installations.
Management says it enters the second half with regained momentum and wants to keep growing at the high end of MedTech. The plan leans on a steady cadence of innovation, including the move to full commercial launches of Triathlon Gold. The main tension is supply: demand is described as strong, so clearing backorders and avoiding further disruption matters most.
No call transcript for this quarter, so this summary also draws on: Webull (Motley Fool transcript) ↗.
Key numbers
- Net sales · GAAP
- $6.6B
- Net earnings · GAAP
- $1.3B
- Reported diluted EPS · GAAP
- $3.30
- Adjusted diluted EPS · non-GAAP
- $3.69
- Gross profit margin · GAAP
- 68.3%
- Operating income · GAAP
- $1.7B
- Operating income margin · GAAP
- 25.2%
- Adjusted operating income margin · non-GAAP
- 27.4%
up 9.4% from a year ago
up 44.3% from a year ago
up 44.1% from a year ago
up 17.9% from a year ago
up 49.1% from a year ago
up 170 bps from a year ago
| Segment or metric | Value | Change |
|---|---|---|
| MedSurg and Neurotechnology | $3.6B | up 9.7% as reported |
| Orthopaedics | $3.0B | up 9.1% as reported |
| Medical | $1.1B | up 13.4% as reported |
| Endoscopy | $1.0B | up 11.7% as reported |
| Instruments | $1.0B | up 9.3% as reported |
| Vascular | $496.0M | down 0.7% as reported |
| Trauma and Extremities | $1.1B | up 11.9% as reported |
| Knees | $693.0M | up 8.4% as reported |
Where each number comes from
- Net sales: “Net sales | $6,589 | $6,022 | 9.4% | $12,609 | $11,888 | 6.1% Cost of sales | 2,091 | 2,181”
- Net earnings: “Net earnings | $1,276 | $884 | 44.3% | $2,021 | $1,538 | 31.4% Net earnings per share of common stock: Basic”
- Reported diluted EPS: “Reported EPS increased 44.1% to $3.30 •Adjusted EPS(1) increased 17.9% to $3.69”
- Adjusted diluted EPS: “Reported EPS increased 44.1% to $3.30 •Adjusted EPS(1) increased 17.9% to $3.69”
- Gross profit margin: “Reported gross profit margin and reported operating income margin were 68.3% and 25.2% in the quarter.”
- Operating income: “Operating income | $1,659 | $1,113 | 49.1% | $2,595 | $1,950 | 33.1% % of sales | 25.2% | 18.5%”
- Operating income margin: “Reported gross profit margin and reported operating income margin were 68.3% and 25.2% in the quarter.”
- Adjusted operating income margin: “Adjusted operating income margin(1) increased 170 bps to 27.4% •Reported EPS increased 44.1% to $3.30”
- MedSurg and Neurotechnology: “MedSurg and Neurotechnology United States | $2,854 | $2,626 | 8.7% | 8.7% | $5,348 | $5,043 | 6.1% | 6.1% International | 771 | 679 | 13.3 | 11.1 | 1,484 | 1,318 | 12.5 | 8.1 Total | $3,625 | $3,305 | 9.7%”
- Orthopaedics: “Total | $2,964 | $2,717 | 9.1% | 8.7% | $5,777 | $5,527 | 4.5% | 3.3% Geographic: United States | $4,959 | $4,554”
- Medical: “Total | $1,122 | $990 | 13.4% | 13.0% | $2,024 | $1,935 | 4.6% | 3.9% Vascular United States | $250 | $268”
- Endoscopy: “Total | $1,004 | $899 | 11.7% | 11.3% | $1,872 | $1,766 | 6.0% | 5.3% Medical United States | $945 | $840”
- Instruments: “Total | $1,003 | $918 | 9.3% | 9.0% | $1,923 | $1,756 | 9.6% | 8.9% Endoscopy United States | $819 | $742”
- Vascular: “Total | $496 | $498 | (0.7)% | (1.8)% | $1,013 | $904 | 11.9% | 9.9% MedSurg and Neurotechnology United States”
- Trauma and Extremities: “Total | $1,072 | $957 | 11.9% | 11.5% | $2,107 | $1,902 | 10.7% | 9.4% Ortho Tech United States | $530 | $483”
- Knees: “Total | $693 | $640 | 8.4% | 8.0% | $1,363 | $1,279 | 6.6% | 5.3% Hips United States | $296 | $283”
Copied from the press release ↗ and other documents in the SEC filing ↗. A figure is published only if its sentence is in those documents.
| From the filing | Q2 2026 | vs year ago | vs last quarter |
|---|---|---|---|
| Revenue | $6.6B | +9.4% | +9.5% |
| Operating income | $1.7B | +49.1% | +77.2% |
| Net income | $1.3B | +44.3% | +71.3% |
| Diluted EPS | $3.30 | +44.1% | +71.0% |
| Free cash flow | $1.1B | +14.1% | +155.2% |
| Gross margin | 68.3% | +4.5 pts | +5.0 pts |
| Operating margin | 25.2% | +6.7 pts | +9.7 pts |
Calculated by code from XBRL, not by the model.
Outlook
| Metric | Period | Outlook |
|---|---|---|
| Organic net sales growth | full year 2026 | 8.3% to 9.3% |
| Adjusted net earnings per diluted share | full year 2026 | $14.95 to $15.10 |
Key takeaways
Cyber incident recovery drove supply and sales
Production ramped as recovery continued, but the supply disruption created a meaningful backorder situation with lost sales in the quarter. Restoring supply is the main near-term operating task.
Mako had its best ever Q2 installations
Stryker focused more on competitive users than on existing Stryker users in these installations, which suggests the robot is winning share from rivals rather than only expanding inside its base.
Triathlon Gold is moving to full commercial launch
Management said it is rapidly moving to full commercial launches of Triathlon Gold, extending its knee portfolio, where Knees sales grew 8.4% in the quarter.
Demand is not the constraint, backlog is
Management said orders are already there and that there have been zero cancellations in its books. Backordered demand remains to be fulfilled as supply recovers.
New competitors are limited to part of the market
Management said some new competitors tend to be more in just the aspiration portion of the market. Stryker is therefore not seeing broad competitive pressure across its robotic offering.
Charts
Data
| Q4 2024 | $6.4B |
| Q1 2025 | $5.9B |
| Q2 2025 | $6.0B |
| Q3 2025 | $6.1B |
| Q4 2025 | $7.2B |
| Q1 2026 | $6.0B |
| Q2 2026 | $6.6B |
| Q3 2026 | $6.5B |
Data
| Q4 2024 | $1.41 |
| Q1 2025 | $1.69 |
| Q2 2025 | $2.29 |
| Q3 2025 | $2.22 |
| Q4 2025 | $2.20 |
| Q1 2026 | $1.93 |
| Q2 2026 | $3.30 |
| Q3 2026 | $1.96 |
Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.
Data
| Q4 2024 | 9.0% |
| Q1 2025 | 14.3% |
| Q2 2025 | 18.5% |
| Q3 2025 | 18.7% |
| Q4 2025 | 25.2% |
| Q1 2026 | 15.5% |
| Q2 2026 | 25.2% |
| Q3 2026 | 15.9% |
Data
| Q4 2024 | $1.7B |
| Q1 2025 | $127.0M |
| Q2 2025 | $928.0M |
| Q3 2025 | $1.4B |
| Q4 2025 | $1.9B |
| Q1 2026 | $415.0M |
| Q2 2026 | $1.1B |
| Q3 2026 | $1.2B |
Operating cash flow minus capital expenditure, from cash flow statements.
Questions
How did the cyber incident affect Stryker's business this quarter?
Stryker's recovery continued as it ramped overall production, but the supply disruption resulted in a meaningful backorder situation with lost sales. Management said it made significant progress in recovering and enters the second half with regained momentum.
How is Mako performing?
Stryker delivered its best ever Q2 for Mako installations. It focused more on competitive users than existing Stryker users.
Is demand for Stryker's products healthy?
Management said orders are already there, so demand is not the problem, and it has seen zero cancellations in its books. Organic sales growth came from increased unit volume.
What new products is Stryker launching?
Stryker said it is rapidly moving to full commercial launches of Triathlon Gold. The sources give no further detail on launch timing.
Is Stryker facing new competition?
Management said there are some new competitors, which tend to be more in just the aspiration portion of the market. Stryker also faces pricing pressure and changes in the competitive environment as listed risks.
Documents
From Stryker investor relations
SEC filing